Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.92 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.92 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.92 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.92 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.92 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.92 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.92 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.92 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.92 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30714411 | 1.00 | HDAC6 (0.92) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Hydrochloric Acid SCHEMBL2783279 | 0.99 | HDAC6 (0.90) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL9950832 | 0.96 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL29394147 | 0.96 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL26319 | 0.96 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL18843 | 0.95 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL15523734 | 0.95 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL12497247 | 0.95 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL29352819 | 0.95 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL29988092 | 0.95 | HDAC6 (0.82) | HDAC6HDAC1HDAC3HDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2985038-A1 | Lyophilized API preparation | Azad Pharma AG (CH) | 2016-02-17 | — | — | EP | claimed |
| US-20250387374-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE | AZURITY PHARMACEUTICALS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12208086-B2 | Stable pharmaceutical compositions of bendamustine | SLAYBACK PHARMA LLC (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240075014-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE | SLAYBACK PHARMA LLC (US) | 2024-03-07 | — | — | US | disclosed |
| US-11844784-B2 | Stable pharmaceutical compositions of bendamustine | SLAYBACK PHARMA LLC (US) | 2023-12-19 | — | — | US | disclosed |
| US-11826466-B2 | Bendamustine solution formulations | NAVINTA, LLC (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826466-B2 | Bendamustine solution formulations | NAVINTA, LLC (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230364017-A1 | BENDAMUSTINE SOLID DISPERSIONS AND CONTINUOUS INFUSION | VOUDOURIS VASILIOS (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230310381-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | VOUDOURIS VASILIOS (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230310384-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE | SLAYBACK PHARMA LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20120003305-A1 | Oral Dosage Forms Of Bendamustine | ASTELLAS DEUTSCHLAND GMBH (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20120003305-A1 | Oral Dosage Forms Of Bendamustine | ASTELLAS DEUTSCHLAND GMBH (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20120003305-A1 | Oral Dosage Forms Of Bendamustine | ASTELLAS DEUTSCHLAND GMBH (DE) | 2012-01-05 | — | — | US | disclosed |
| WO-2011103150-A2 | LYOPHILIZED PREPARATIONS OF BENDAMUSTINE | CEPHALON, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20110190363-A1 | LIQUID FORMULATIONS OF BENDAMUSTINE | CEPHALON, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190363-A1 | LIQUID FORMULATIONS OF BENDAMUSTINE | CEPHALON, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2011079193-A2 | PREPARATION OF BENDAMUSTINE AND ITS SALTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-06-30 | — | — | WO | disclosed |
| WO-2010063493-A1 | ORAL DOSAGE FORMS OF BENDAMUSTINE | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010063476-A2 | SOLID DOSAGE FORMS OF BENDAMUSTINE | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010036702-A1 | LIQUID FORMULATIONS OF BENDAMUSTINE | CEPHALON, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003305-A1 | Oral Dosage Forms Of Bendamustine | TAS2R42, TAS2R40, TAS2R45 | HDAC6 1882/4885HDAC1 2640/4885HDAC3 2999/4885 |
| US-11826466-B2 | Bendamustine solution formulations | BHMT, BHMT2, BAD | HDAC6 1244/4885HDAC1 1909/4885HDAC3 3451/4885 |
| US-20230310384-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE | SORD, NONO, SBDS | HDAC6 1384/4885HDAC1 3398/4885HDAC3 3707/4885 |
| US-20240075014-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE | SORD, NONO, SBDS | HDAC6 1384/4885HDAC1 3398/4885HDAC3 3707/4885 |
| US-11844784-B2 | Stable pharmaceutical compositions of bendamustine | SORD, NONO, SBDS | HDAC6 1384/4885HDAC1 3398/4885HDAC3 3707/4885 |
| US-20230310381-A1 | BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | FLT3, BLK, FOLR2 | HDAC6 1308/4885HDAC1 3917/4885HDAC3 4356/4885 |
| US-20110190363-A1 | LIQUID FORMULATIONS OF BENDAMUSTINE | EML4, ABCB1, BLK | HDAC6 2174/4885HDAC1 2740/4885HDAC3 3257/4885 |
| US-20250387374-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE | BCL6, BCL9, BCL6B | HDAC6 2046/4885HDAC1 3049/4885HDAC3 3514/4885 |
| US-12208086-B2 | Stable pharmaceutical compositions of bendamustine | SORD, NONO, SBDS | HDAC6 1384/4885HDAC1 3398/4885HDAC3 3707/4885 |
| US-20230364017-A1 | BENDAMUSTINE SOLID DISPERSIONS AND CONTINUOUS INFUSION | WEE1, SLC29A2, SLC29A1 | HDAC6 1618/4885HDAC1 2772/4885HDAC3 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.